利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.027 秒)

    Piperazine compounds
    5.
    发明申请
    Piperazine compounds 失效
    哌嗪化合物

    公开(公告)号：US20060229318A1

    公开(公告)日：2006-10-12

    申请号：US11395747

    申请日：2006-03-31

    申请人： Jean-Louis Peglion ,  Aimee Dessinges ,  Bertrand Goument ,  Mark Millan ,  Clotilde La Cour

    发明人： Jean-Louis Peglion ,  Aimee Dessinges ,  Bertrand Goument ,  Mark Millan ,  Clotilde La Cour

    IPC分类号： A61K31/496 ,  A61K31/495 ,  C07D405/02

    CPC分类号： C07D313/08 ,  C07D211/22 ,  C07D213/81 ,  C07D215/42 ,  C07D243/08 ,  C07D249/12 ,  C07D295/096 ,  C07D295/155 ,  C07D311/68 ,  C07D319/20 ,  C07D405/04

    摘要： A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.

    摘要翻译： 选自式（I）的化合物的化合物：其中：R 1，R 2，R 3和R 4， 可以相同或不同，各自表示选自氢，卤素，烷基，烷氧基，苯基和氰基的原子或基团，X表示键，氧原子或选自 - （CH 2） 其中m表示1或2，R 1，R 2，R 3，R 5， SUB> 5 如说明书中所定义，Y表示氧原子或选自NR 7和CHR 8的基团，其中R 7 R 3和R 8如说明书中所定义，Z表示氮原子或CH基团，n表示1或2，Ak表示亚烷基链，Ar表示芳基或杂芳基 ，其光学异构体及其与药学上可接受的酸的加成盐。 含有该药物的医药产品可用于治疗需要5-羟色胺再摄取抑制剂和/或NK1拮抗剂的病症。

    Piperazine compounds
    7.
    发明申请
    Piperazine compounds 失效
    哌嗪化合物

    公开(公告)号：US20090076030A1

    公开(公告)日：2009-03-19

    申请号：US12291485

    申请日：2008-11-10

    申请人： Jean-Louis Peglion ,  Aimee Dessinges ,  Bertrand Goument ,  Mark Millan ,  Clotilde Mannoury La Cour

    发明人： Jean-Louis Peglion ,  Aimee Dessinges ,  Bertrand Goument ,  Mark Millan ,  Clotilde Mannoury La Cour

    IPC分类号： A61K31/496 ,  C07D241/04 ,  C07D405/04 ,  A61K31/495 ,  A61P25/22 ,  A61P25/24 ,  A61P1/00 ,  A61K31/4965 ,  C07D241/02

    CPC分类号： C07D313/08 ,  C07D211/22 ,  C07D213/81 ,  C07D215/42 ,  C07D243/08 ,  C07D249/12 ,  C07D295/096 ,  C07D295/155 ,  C07D311/68 ,  C07D319/20 ,  C07D405/04

    摘要： A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.

    摘要翻译： 选自式（I）的化合物：其中：R 1，R 2，R 3和R 4可以相同或不同，表示选自氢，卤素，烷基，烷氧基，苯基和氰基的原子或基团，X 表示键，氧原子或选自 - （CH 2）m - ， - OCH 2 - 和-NR 5 - 的基团，其中m表示1或2，R 5如说明书中所定义，Y表示氧原子或 选自NR7和CHR8的基团，其中R7和R8如说明书中所定义，Z表示氮原子或CH基团，n表示1或2，Ak表示亚烷基链，Ar表示芳基或杂芳基，其光学 异构体及其与药学上可接受的酸的加成盐。 含有该药物的药物可用于治疗需要5-羟色胺再摄取抑制剂和/或NK1拮抗剂的病症。

    1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them
    10.
    发明授权
    1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them 有权
    1,2,4,5-四氢-3H-苯并氮杂化合物，其制备方法和含有它们的药物组合物

    公开(公告)号：US08076325B2

    公开(公告)日：2011-12-13

    申请号：US12283110

    申请日：2008-09-09

    申请人： Jean-Louis Peglion ,  Bertrand Goument ,  Aimee Dessinges ,  Pascal Caignard ,  Jean-Paul Vilaine ,  Catherine Thollon ,  Nicole Villeneuve ,  Stefano Chimenti

    发明人： Jean-Louis Peglion ,  Bertrand Goument ,  Aimee Dessinges ,  Pascal Caignard ,  Jean-Paul Vilaine ,  Catherine Thollon ,  Nicole Villeneuve ,  Stefano Chimenti

    IPC分类号： A01N43/00 ,  A61K31/55 ,  C07D223/16

    CPC分类号： C07D223/16

    摘要： Compounds of formula (I): wherein: R1 represents a hydrogen atom or a group selected from cycloalkyl, benzyl and optionally substituted alkyl, R2, R3, R4 and R5 each represent a hydrogen atom or a hydroxy, methyl, —OSO2R10, —OCOR10 or optionally substituted alkoxy group, or R2 and R3, or R3 and R4, or R4 and R5 together form a group —O—(CH2)q—O—, —O—CH═CH—O— or —O—CH═CH—, R6, R7, R8 and R9 each represent a hydrogen atom or an alkoxy group, or R6 and R7, or R7 and R8, or R8 and R9 together form a group —O—(CH2)q—O—, R10 represents a group selected from linear or branched C1-C6alkoxy, NR11R′11 and optionally substituted alkyl, R11 and R′11 each represent a hydrogen atom or an alkyl group, or R11 and R′11 together with the nitrogen atom carrying them form an optionally substituted, monocyclic or bicyclic, nitrogen-containing heterocycle, X represents O, NH or CH2, m and p each represent 0 or 1, n and q each represent 1 or 2, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating various pathologies.

    摘要翻译： 式（I）化合物：其中：R 1表示氢原子或选自环烷基，苄基和任选取代的烷基的基团，R 2，R 3，R 4和R 5各自表示氢原子或羟基，甲基，-OSO 2 R 10，-OCOR 10 或任选取代的烷氧基，或R 2和R 3，或R 3和R 4，或R 4和R 5一起形成基团-O-（CH 2）q -O-，-O-CH = CH-O-或-O-CH = CH-，R6，R7，R8和R9各自表示氢原子或烷氧基，或R6和R7，或R7和R8，或R8和R9一起形成-O-（CH 2）q -O-，R 10基团 表示选自直链或支链C 1 -C 6烷氧基，NR 11 R 11和任选取代的烷基的基团，R 11和R 11各自表示氢原子或烷基，或者R 11和R 11与携带它们的氮原子一起形成 任选取代的单环或双环含氮杂环，X表示O，NH或CH 2，m和p各自表示0或1，n和q各自表示1或2，以外消旋形式或i n是光学异构体的形式，以及其与药学上可接受的酸的加成盐。 含有该药物的药物可用于治疗各种病症。